First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies	Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, adenoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, epithelial neoplasm, hormone-resistant breast carcinoma, lung disorder, lung neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 1	2022-11-28		NCT05627960

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
A&G Pharmaceutical Inc.	1
University of Maryland Greenebaum Cancer Center	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of Maryland Greenebaum Comprehensive Cancer Center	Baltimore	United States	20